A study published by Eurostat in September 2017 shows that despite significant advances in the fight against cancer, this disease remains an important concern for EU countries, being the second most common cause of deaths on the continent.
In 2014, 1,300,000 people died of cancer, accounting for 26.4% of the total deaths, of which 29.7% were among men and 23.2% among women. Germany ranks first, followed by Italy and the UK, while Romania ranked 8th with over 50,000 deaths. As far as statistics on operations and treatments for this medical condition are concerned, more than 440 / 100,000 inhabitants have been carried out in our country, a number that has doubled since 2010.
Taking these indices into account regarding the state of health of the population at a national and international level, access to private health insurance is of particular importance, as it offers the recipient financial security in difficult medical situations.
Private health insurance covers the high costs of treatments or interventions, helping the holder and his family to overcome critical moments. Based on the policy, the beneficiary can choose any clinic or private hospital in the country or abroad, benefiting from services at the highest standards. In addition, the insurance can be used in cases of emergency, air discharge, hospitalization, surgery and treatments, including for cancer, as well as routine consultations or check-ups, says Zahal Levy, President of MediHelp International.
To further support people experiencing such a health problem, MediHelp International, together with its British partner LAMP Insurance and in collaboration with The New European Surgical Academy (an international academy that brings together opinion leaders from the field of oncology and oncology surgery, with members in 54 countries) created NESAcard. This is the solution for medical navigation and second medical opinion when diagnosed with cancer. Also, the card provides a cash benefit or reimbursement for initial investigations. Thus, a contribution of 33 euros per year provides the beneficiary with the guarantee of financial support in investigation and cancer diagnosis.